News | May 11, 2022
Bayer posts higher sales, profit in first quarter
Company's net income rose by 57.5 percent to 3.291 billion euros in Q1
Company's net income rose by 57.5 percent to 3.291 billion euros in Q1
Aflibercept is the second biosimilar product that has entered the clinical trial phase after biosimilar Adalimumab
Appoints Dr Rafiq Hasan as CEO
The companies will continue with their exclusive agreements, including commercialization of their current portfolio
It becomes the first ophthalmology biosimilar to gain FDA approval in the United States
Bayer Zydus Pharma will continue to operate in core therapies with new products in the pipeline
Subscribe To Our Newsletter & Stay Updated
